Enhancing Stroke Recovery Through Cortical Stimulation: The Role of the Ipsilateral Motor Cortex in Executing Movements With Increasing Demand on Precision

Role of Ipsilateral Motor Cortex in Executing Movements With Increasing Demand on Precision


Lead sponsor: Cathrin Buetefisch

Collaborator: National Institutes of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)

Source Emory University
Brief Summary

It is well known that the motor area of one hemisphere of the brain (motor cortex) controls the movement of the opposite of the body. However, it is not clear whether as the movement becomes more complicated, the motor cortex of both hemispheres of the brain are involved. Currently the role of the motor cortex on the same side of the body (referred to as ipsilateral motor cortex) in hand performance remains controversial. The investigators demonstrated previously in healthy subjects that transiently lowering the activity of ipsilateral motor cortex improved the performance of the opposite hand. What is not know are the mechanisms involved in these changes of behavior. Transcranial magnetic stimulation (TMS) is a device that allows the non- invasive stimulation of the brain. When brain is stimulated repetitively at a very low rate and low intensity for about 15 minutes, the stimulated brain area becomes less active. This effect lasts 10 minutes and is called a "transient artificial lesion" as it mimicks the effects of transiently interfering with the function of the stimulated brain area. In the present study the investigators will conduct experiments using repetitive TMS to downregulate the activity of the motor area as in previous experiments and measures its effect on activity of motor cortex of both hemispheres. The investigators will study healthy subjects. It would be important to understand the effects in more detail for the design of treatment strategies in patients after stroke, which will be a topic of future studies.

Overall Status Completed
Start Date May 2011
Completion Date March 26, 2015
Primary Completion Date March 26, 2015
Study Type Observational
Primary Outcome
Measure Time Frame
Define key parameters that contribute to contralesional M1 reorganization following stroke Up to six months post-stroke
Enrollment 20

Sampling method: Non-Probability Sample


Inclusion Criteria for Stroke Patients:

- Age 18-80

- Single cerebral ischemic infarction one month prior to entering study

- Affecting only one hemisphere as defined by MRI of the brain

- At the time of cerebral infarct a motor deficit of hand of Medical Research Council Scale for Muscle Strength (MRC) of < 4- of wrist and finger extension/flexion movement

- Fugl Meyer score > 27/66 (motor domain, upper extremity)

- Ability to operate joystick at largest target level

- No other neurological disorder

- No intake of Central Nervous System (CNS) active drugs

- Ability to give informed consent

- Ability to meet criteria of inclusion experiment

- No major cognitive impairment

Inclusion Criteria for Healthy Subjects:

- Age 55-80 years with no neurological or psychiatric diseases

- Normal neurological examination

- Normal MRI of the brain

- Normal neuropsychological testing

- No intake of CNS active drugs that interfere with data collection

- No contraindication to TMS

- Ability to give informed consent

Gender: All

Minimum age: 18 Years

Maximum age: 80 Years

Healthy volunteers: Accepts Healthy Volunteers

Overall Official
Last Name Role Affiliation
Cathrin Buetefisch, MD, PhD Principal Investigator Emory University
facility Emory University School of Medicine
Location Countries

United States

Verification Date

October 2018

Responsible Party

Responsible party type: Sponsor-Investigator

Investigator affiliation: Emory University

Investigator full name: Cathrin Buetefisch

Investigator title: Dr Cathrin Buetefisch, M.D., PhD

Has Expanded Access No
Condition Browse
Arm Group

Arm group label: Stroke patients

Arm group label: Healthy Control

Acronym RIMC
Study Design Info

Observational model: Case-Control

Time perspective: Prospective

Source: ClinicalTrials.gov